Search
healthcare › ... › breast-cancer
… St. Luke's Medical Center, our physicians are among the best in their field. They are committed to innovative, …
departments › ... › benefits-and-wellness
… a place that felt more like home.” - Chris Denny, Class of 2022 “When I came to interview for fellowship, my family and … “Houston has it all – it’s a great foodie town – has the best Chinese food hands down (even has its own … school and lots of kids in the neighborhood. Was named best city to live in the United States per a USA Today …
healthcare › ... › pagets-disease-of-the-vulva
… this condition should be closely monitored through regular visits to their OB/GYN. Paget’s disease can also affect the …
research › ... › cmmr-sequencing-center
… sample processing, metagenomic sequencing, and analytical tool development. Partnering with over 300 global research … pandemic, it processed over 163,000 testing samples for Houston and Harris County. Since 2022, it has partnered with the … Institute’s TexWEB network, developing sequencing pipelines to monitor microbial threats in Texas wastewater. The CMMR’s …
departments › ... › chiefs-message
… (IQuESt) . Whether you’re a prospective trainee, collaborator, or just exploring our work, we invite you to learn more … Grand Rounds seminars, including Research in Progress, Visiting Professors, Job Talks, and Workshops. The … Welcome to the Section of Health Services Research …
education › ... › ccb-videos
… The best way to learn about what life will be like as a student …
academic-centers › ... › project-3
… Limited sensitivity to chemotherapy and an immunosuppressive tumor … IRE1/XBP1 pathway with a highly selective IRE1 RNase inhibitor ORIN1001 suppresses MYC-high-expressing (MYChigh), but … of the IRE1/XBP1 pathway with the IRE1 inhibitor ORIN1001 compromises MYChigh breast cancers by inhibiting obligatory …
healthcare › clinical-trials › h-41818
… The purpose of this study is to find out if adding simvastatin (an oral medication approved by the FDA to treat high cholesterol) to dual … even when the HER2 protein is blocked. When this happens, the cancer will start to grow again. Researchers … SIMPHONY: A Trial Adding Simvastatin to Dual Anti-HER2 Therapy in Patients with HER2-positive …
healthcare › clinical-trials › h-50373
… phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy … return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone. For more information: …
education › ... › forms
… System (ENS) as needed. To keep your information updated, visit the ENS site (login required). … Research Visitor/Volunteer Education Forms …